Pristane-induced lupus as a model of human lupus arthritis: Evolvement of autoantibodies, internal organ and joint inflammation

Lupus

Volumn 22, Issue 8, 2013, Pages 778-792

  Leiss, H ^a   Niederreiter, B ^a   Bandur, T ^a   Schwarzecker, B ^a   Bluml S ^a   Steiner, G ^a   Ulrich, W ^b   Smolen, J S ^a   Stummvoll, G H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital   (Austria)

Author keywords

Lupus arthritis; pristane induced lupus (PIL); systemic lupus erythematosus (SLE)

Indexed keywords

HISTONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PRISTANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CHROMATIN; CLINICAL FEATURE; CONTROLLED STUDY; CORTICAL BONE; CYTOMETRY; EROSION; FEMALE; GRANULOCYTE; HISTOPATHOLOGY; IMAGE ANALYSIS; INFLAMMATORY CELL; JOINT; JOINT DESTRUCTION; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOCLAST; PANNUS; PRIORITY JOURNAL; PRISTANE INDUCED LUPUS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

LUPUS ARTHRITIS; PRISTANE-INDUCED LUPUS (PIL); SYSTEMIC LUPUS ERYTHEMATOSUS (SLE);

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GRANULOCYTES; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SEVERITY OF ILLNESS INDEX; SPECIES SPECIFICITY; TERPENES; TIME FACTORS;

EID: 84879697143     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313492869     Document Type: Article

References (66)

1. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA. 1964 ; 190: 104-111
2. Grigor R, Edmonds J, Lewkonia R, Bresnihan B, Hughes GR. Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis. 1978 ; 37: 121-128
3. Stamm TA, Bauernfeind B, Coenen M, et al. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum. 2007 ; 57: 1287-1295
4. Bauernfeind B, Aringer M, Prodinger B, et al. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum. 2009 ; 61: 21-28
5. van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis. 1998 ; 57: 540-544
6. Boutry N, Hachulla E, Flipo RM, Cortet B, Cotten A. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren syndrome. Radiology. 2005 ; 236: 593-600
7. Ostendorf B, Scherer A, Specker C, Mödder U, Schneider M. Jaccoud's arthropathy in systemic lupus erythematosus: Differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum. 2003 ; 48: 157-165
8. Armas-Cruz R, Harnecker J, Ducach G, Jalil J, Gonzalez F. Clinical diagnosis of systemic lupus erythematosus. Am J Med. 1958 ; 25: 409-419
9. Cruickshank B. Lesions of joint and tendon sheaths in systemic lupus erythematosus. Ann Rheum Dis. 1959 ; 18: 111-119
10. Goldenberg DL, Cohen AS. Synovial membrane histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease. Medicine (Baltimore). 1978 ; 57: 239-252
11. Labowitz R, Schumacher HR. Articular manifestations of systemic lupus erythematosus. Ann Intern Med. 1971 ; 74: 911-921
12. Natour J, Montezzo LC, Moura LA, Atra E. A study of synovial membrane of patients with systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 1991 ; 9: 221-225
13. Wallace D Dubois' Lupus Erythematosus. 5 th ed. Baltimore, MD: Williams & Wilkins, 1997, pp. 635-651. Wallace D, ed. Baltimore, MD: Williams & Wilkins ; 1997: 635-651.
14. Ito MR, Terasaki S, Itoh J, Katoh H, Yonehara S, Nose M. Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. Arthritis Rheum. 1997 ; 40: 1054-1063
15. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009 ; 30: 455-464
16. Furukawa F, Tanaka H, Sekita K, Nakamura T, Horiguchi Y, Hamashima Y. Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res. 1984 ; 276: 186-194
17. Furukawa F, Yoshimasu T. Animal models of spontaneous and drug-induced cutaneous lupus erythematosus. Autoimmun Rev. 2005 ; 4: 345-350
18. Hang L, Theofilopoulos AN, Dixon FJ. A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J Exp Med. 1982 ; 155: 1690-1701
19. Koopman WJ, Gay S. The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand J Rheumatol Suppl. 1988 ; 75: 284-289
20. Dahlgren J, Takhar H, Anderson-Mahoney P, Kotlerman J, Tarr J, Warshaw R. Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: A cross sectional study. Environ Health. 2007 ; 6: 8-8
21. Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999 ; 107: 743-748
22. Satoh M, Kuroda Y, Yoshida H, et al. Induction of lupus autoantibodies by adjuvants. J Autoimmun. 2003 ; 21: 1-9
23. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother. 2004 ; 58: 325-337
24. Wooley PH, Sud S, Whalen JD, Nasser S. Pristane-induced arthritis in mice. V. Susceptibility to pristane-induced arthritis is determined by the genetic regulation of the T cell repertoire. Arthritis Rheum. 1998 ; 41: 2022-2031
25. Chapdelaine JM, Whalen JD, Wooley PH. Pristane induced arthritis. II. Genetic regulation in F1 hybrid mice and cellular immune abnormalities following pristane injection. Autoimmunity. 1991 ; 8: 215-220
26. Wooley PH, Seibold JR, Whalen JD, Chapdelaine JM. Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum. 1989 ; 32: 1022-1030
27. Potter M, Wax JS. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: Reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol. 1981 ; 127: 1591-1595
28. Patten C, Bush K, Rioja I, et al. Characterization of pristane-induced arthritis, a murine model of chronic disease: Response to antirheumatic agents, expression of joint cytokines, and immunopathology. Arthritis Rheum. 2004 ; 50: 3334-3345
29. Hopkins SJ, Freemont AJ, Jayson MI. Pristane-induced arthritis in Balb/c mice. I. Clinical and histological features of the arthropathy. Rheumatol Int. 1984 ; 5: 21-28
30. Bedwell AE, Elson CJ, Hinton CE. Immunological involvement in the pathogenesis of pristane-induced arthritis. Scand J Immunol. 1987 ; 25: 393-398
31. Hayer S, Redlich K, Korb A, Hermann S, Smolen J, Schett G. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum. 2007 ; 56: 79-88
32. Blüml S, Binder NB, Niederreiter B, et al. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 2010 ; 62: 1608-1619
33. Zwerina K, Koenders M, Hueber A, et al. Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol. 2012 ; 42: 413-423
34. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002 ; 110: 1419-1427
35. Paisansinsup T, Deshmukh US, Chowdhary VR, Luthra HS, Fu SM, David CS. HLA class II influences the immune response and antibody diversification to Ro60/Sjögren's syndrome-A: Heightened antibody responses and epitope spreading in mice expressing HLA-DR molecules. J Immunol. 2002 ; 168: 5876-5884
36. Dumortier H, Monneaux F, Jahn-Schmid B, et al. B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J Immunol. 2000 ; 165: 2297-2305
37. Yang JY, Oh EJ, Kim Y, Park YJ. Evaluation of anti-dsDNA antibody tests: Crithidia luciliae immunofluorescence test, immunoblot, enzyme-linked immunosorbent assay, chemiluminescence immunoassay [in Korean]. Korean J Lab Med. 2010 ; 30: 675-684
38. Melegari A, Bonaguri C, Russo A, Luisita B, Trenti T, Lippi G. A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun Rev. 2012 ; 11: 713-716
39. Hayer S, Redlich K, Korb A, Hermann S, Smolen J, Schett G. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum. 2007 ; 56: 79-88
40. Schett G, Tuerk B. Bone histomorphometry in arthritis models. Methods Mol Med. 2007 ; 135: 269-283
41. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987 ; 2: 595-610
42. Redlich K, Görtz B, Hayer S, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol. 2004 ; 164: 543-555
43. Eferl R, Hasselblatt P, Rath M, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA. 2008 ; 105: 10525-10530
44. Leonard JP, Lacasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 ; 119: 4597-4607
45. Blüml S, Bonelli M, Niederreiter B, et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011 ; 63: 1281-1288
46. Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. Interleukin 6 dependence of anti-DNA antibody production: Evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med. 1998 ; 188: 985-990
47. Savarese E, Steinberg C, Pawar RD, et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 2008 ; 58: 1107-1115
48. Hopkins SJ, Freemont AJ, Jayson MI. Pristane-induced arthritis in BALB/c mice. Curr Top Microbiol Immunol. 1985 ; 122: 213-220
49. Jiménez-Boj E, Redlich K, Turk B, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol. 2005 ; 175: 2579-2588
50. Hayer S, Polzer K, Brandl A, et al. B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res. 2008 ; 23: 1650-1660
51. Chowdhary VR, Grande JP, Luthra HS, David CS. Characterization of haemorrhagic pulmonary capillaritis: Another manifestation of pristane-induced lupus. Rheumatology (Oxford). 2007 ; 46: 1405-1410
52. Barker TT, Lee PY, Kelly-Scumpia KM, et al. Pathogenic role of B cells in the development of diffuse alveolar hemorrhage induced by pristane. Lab Invest. 2011 ; 91: 1540-1550
53. Hahn B Dubois' Lupus Erthematosus. 5 th ed. Baltimore, MD: Williams & Wilkins, 1997. Wallace D, ed. Baltimore, MD: Williams & Wilkins ; 1997:
54. Holmdahl R, Mo J, Nordling C, et al. Collagen induced arthritis: An experimental model for rheumatoid arthritis with involvement of both DTH and immune complex mediated mechanisms. Clin Exp Rheumatol. 1989 ;: S51 - S55
55. Holmdahl R, Andersson ME, Goldschmidt TJ, et al. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS. 1989 ; 97: 575-584
56. Boumpas DT, Eleftheriades EG, Tsokos GC. Cellular immunity in systemic lupus erythematosus. In Vivo. 1988 ; 2: 41-45
57. Hamilton KJ, Satoh M, Swartz J, Richards HB, Reeves WH. Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin Immunol Immunopathol. 1998 ; 86: 271-279
58. Satoh M, Kumar A, Kanwar YS, Reeves WH. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA. 1995 ; 92: 10934-10938
59. Calvani N, Satoh M, Croker BP, Reeves WH, Richards HB. Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. Kidney Int. 2003 ; 64: 897-905
60. Levitt NG, Fernandez-Madrid F, Wooley PH. Pristane induced arthritis in mice. IV. Immunotherapy with monoclonal antibodies directed against lymphocyte subsets. J Rheumatol. 1992 ; 19: 1342-1347
61. Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. Interleukin 6 dependence of anti-DNA antibody production: Evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med. 1998 ; 188: 985-990
62. Richards HB, Satoh M, Jennette JC, Croker BP, Yoshida H, Reeves WH. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 2001 ; 60: 2173-2180
63. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 1526-1533
64. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: Diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976 ; 55: 323-339
65. Hayahara C, Ikeda K, Sakanishi Y, Ota T. Incidence of serum rheumatoid factors in elder non-rheumatic individuals [in Japanese]. Rinsho Byori Jpn J Clin Pathol. 2010 ; 58: 211-215
66. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011 ; 63: 191-200